Skip to main content
main-content

The independent medical news service

30-04-2021 | Oncology | News | Article

Breast conserving therapy may be an option for BRCA1/2 variant carriers

Individuals with breast cancer and a BRCA1/2 variant experience comparable survival rates whether they are treated with breast-conserving therapy or mastectomy with or without radiotherapy, Chinese researchers suggest.

29-04-2021 | Oncology | News | Article

Nivolumab–ipilimumab receives nod from EMA for malignant pleural mesothelioma

Click through to read more details

29-04-2021 | Oncology | News | Article

Single COVID-19 vaccine dose insufficient for people with cancer

The booster dose of the Pfizer–BioNTech COVID-19 vaccine should not be delayed in people with cancer, suggest the results of two studies showing insufficient immunogenicity with just the first dose.

28-04-2021 | Oncology | News | Article

AHA issues statement on managing hormonal therapy-related CVD risks

The American Heart Association has released a consensus statement on the management of cardiovascular disease in patients receiving hormonal therapies for breast or prostate cancer.

28-04-2021 | Oncology | Highlight | Article

Cardiovascular AEs of prostate cancer hormone therapies reported

An analysis of the FDA Adverse Event Reporting System has provided detailed insight into cardiovascular adverse events associated with different classes of androgen deprivation therapies.

27-04-2021 | Oncology | News | Article

KEYNOTE-158 points to pembrolizumab potential in advanced mesothelioma

Pembrolizumab monotherapy can achieve responses lasting for more than a year in some patients with previously treated malignant pleural mesothelioma (MPM), suggest phase 2 trial data.

26-04-2021 | Oncology | News | Article

EMA recommends extending osimertinib indication

Find out more about this decision here

26-04-2021 | Oncology | News | Article

Alisertib addition may benefit metastatic breast cancer patients

Women with hormone receptor-positive, HER2-negative metastatic breast cancer derive a significant progression-free survival benefit from the addition of alisertib to paclitaxel, indicate phase 2 trial findings.

23-04-2021 | Oncology | News | Article

Lenvatinib–everolimus has ‘encouraging activity’ in untreated non-clear cell RCC

Previously untreated patients with advanced non-clear cell renal cell carcinoma could benefit from treatment with lenvatinib plus everolimus, suggests a phase 2 study.

22-04-2021 | Oncology | News | Article

Limited evidence to link antihypertensive use to cancer

An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.

21-04-2021 | Oncology | News | Article

Interventions needed to support mammography attendance among Black women

Black race is a significant predictor of nonadherence to scheduled screening mammography appointments, suggests research.

21-04-2021 | Oncology | News | Article

Telemedicine not favored by cancer patients or physicians

The majority of patients with cancer and their physicians report a preference for in-person visits rather than telemedicine consultations, suggest results of a survey carried out at the start of the COVID-19 pandemic.

20-04-2021 | Oncology | News | Article

Retreatment with tremelimumab–durvalumab feasible in mesothelioma patients

The NIBIT-MESO-1 trial suggests that retreatment with tremelimumab plus durvalumab could be a viable option for patients with unresectable mesothelioma who progress after initially benefiting from the combination.

19-04-2021 | Oncology | News | Article

FDA approves sacituzumab govitecan for advanced urothelial cancer

Find out more details about this accelerated approval here

19-04-2021 | Oncology | News | Article

Chemoimmunotherapy may be preferable for KRAS wild-type NSCLC

Chemoimmunotherapy may be a better option than immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer patients with high PD-L1 expression and no KRAS mutations, indicate findings.

16-04-2021 | Oncology | News | Article

ESMO issues recommendations for SCLC management

More information on these Clinical Practice Guidelines available here

16-04-2021 | Oncology | News | Article

Outliers in link between obesity and poor cancer survival reinforced in meta-analysis

Individuals with obesity tend to have worse cancer survival outcomes than those without obesity, unless they have lung cancer, renal cell carcinoma, or melanoma, show findings of a systematic review and meta-analysis.

15-04-2021 | Oncology | News | Article

Sintilimab could be a viable second-line option for advanced squamous NSCLC

Patients with advanced squamous non-small-cell lung cancer derive a significant overall survival benefit from second-line treatment with sintilimab versus docetaxel, suggest results from the Chinese ORIENT-3 trial.

15-04-2021 | Oncology | News | Article

Tislelizumab offers improved outcomes over docetaxel in advanced NSCLC

The anti-PD-1 antibody tislelizumab may improve outcomes relative to docetaxel as a second- or third-line therapy for people with advanced non-small-cell lung cancer, regardless of histology or PD-L1 expression levels, researchers report.

14-04-2021 | Oncology | News | Article

cfDNA integrity a potential biomarker for NACT response in breast cancer

Measuring plasma cell-free DNA integrity could improve the accuracy of MRI for predicting a complete response to neoadjuvant chemotherapy for locally advanced breast cancer, research suggests.

Image Credits